Search Results - Mark Penney

A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection by Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun Ojo, Nelson Liu, Nadia M. Luheshi, Alex Phipps, Karthick Vishwanathan

Connect to this object online.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network by Lourdes Cucurull‐Sanchez, Michael J. Chappell, Vijayalakshmi Chelliah, S. Y. Amy Cheung, Gianne Derks, Mark Penney, Alex Phipps, Rahuman S. Malik‐Sheriff, Jon Timmis, Marcus J. Tindall, Piet H. van derGraaf, Paolo Vicini, James W. T. Yates

Connect to this object online.

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities by Erica L. Bradshaw, Mary E. Spilker, Richard Zang, Loveleena Bansal, Handan He, Rhys D.O. Jones, Kha Le, Mark Penney, Edgar Schuck, Brian Topp, Alice Tsai, Christine Xu, Marjoleen J.M.A. Nijsen, Jason R. Chan

Connect to this object online.

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface by John D. Bagert, Vaheh Oganesyan, Chi-I Chiang, Mike Iannotti, Jia Lin, Chunning Yang, Sterling Payne, Will McMahon, Samuel Edwards, Andrew Dippel, Mark Hutchinson, Fengying Huang, Vineela Aleti, Chendi Niu, Chen Qian, Jessica Denham, Sofia Ferreira, Pallab Pradhan, Mark Penney, Chunlei Wang, Wenhai Liu, Even Walseng, Yariv Mazor

Connect to this object online.